lacosamide and Glioblastoma

lacosamide has been researched along with Glioblastoma* in 2 studies

Other Studies

2 other study(ies) available for lacosamide and Glioblastoma

ArticleYear
CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation.
    Molecular neurobiology, 2018, Volume: 55, Issue:5

    Glioblastoma (GBM) is an aggressive primary brain tumor. The rapid growth and the privileged provenance of the tumor within the brain contribute to its aggressivity and poor therapeutic targeting. A poor prognostic factor in glioblastoma is the deletion or mutation of the Nf1 gene. This gene codes for the protein neurofibromin, a tumor suppressor gene that is known to interact with the collapsin response mediator protein 2 (CRMP2). CRMP2 expression and elevated expression of nuclear phosphorylated CRMP2 have recently been implicated in cancer progression. The CRMP2-neurofibromin interaction protects CRMP2 from its phosphorylation by cyclin-dependent kinase 5 (Cdk5), an event linked to cancer progression. In three human glioblastoma cell lines (GL15, A172, and U87), we observed an inverse correlation between neurofibromin expression and CRMP2 phosphorylation levels. Glioblastoma cell proliferation was dependent on CRMP2 expression and phosphorylation by Cdk5 and glycogen synthase kinase 3 beta (GSK3β). The CRMP2 phosphorylation inhibitor (S)-lacosamide reduces, in a concentration-dependent manner, glioblastoma cell proliferation and induced apoptosis in all three GBM cell lines tested. Since (S)-lacosamide is bioavailable in the brain, we tested its utility in an in vivo orthotopic model of GBM using GL261-LucNeo glioma cells. (S)-lacosamide decreased tumor size, as measured via in vivo bioluminescence imaging, by ~54% compared to vehicle control. Our results introduce CRMP2 expression and phosphorylation as a novel player in GBM proliferation and survival, which is enhanced by loss of Nf1.

    Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Glioblastoma; Humans; Intercellular Signaling Peptides and Proteins; Lacosamide; Mice, Inbred C57BL; Nerve Tissue Proteins; Neurofibromin 1; Phosphorylation

2018
Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article.
    Journal of neurosurgery, 2013, Volume: 118, Issue:6

    The object of this study was to determine the tolerability and activity of lacosamide in patients with brain tumors.. The authors reviewed the medical records at 5 US academic medical centers with tertiary brain tumor programs, seeking all patients in whom a primary brain tumor had been diagnosed and who were taking lacosamide.. The authors identified 70 patients with primary brain tumors and reviewed seizure frequency and toxicities. The majority of the patients had gliomas (96%). Fifty-five (78%) had partial seizures only, and 12 (17%) had generalized seizures. Most of the patients (74%) were started on lacosamide because of recurrent seizures. Forty-six patients (66%) reported a decrease in seizure frequency, and 21 patients (30%) reported stable seizures. Most of the patients (54 [77%]) placed on lacosamide did not report any toxicities.. This retrospective analysis demonstrated that lacosamide was both well tolerated and active as an add-on antiepileptic drug (AED) in patients with brain tumors. Lacosamide's novel mechanism of action will allow for concurrent use with other AEDs, as documented by its activity across many different types of AEDs used in this patient population. Larger prospective studies are warranted.

    Topics: Acetamides; Adult; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Lacosamide; Male; Middle Aged; Prevalence; Retrospective Studies; Secondary Prevention; Seizures; Treatment Outcome

2013